share_log

Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

Benzinga ·  Nov 13 02:03

8 analysts have shared their evaluations of Amicus Therapeutics (NASDAQ:FOLD) during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings35000
Last 30D01000
1M Ago21000
2M Ago02000
3M Ago11000

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $17.5, with a high estimate of $21.00 and a low estimate of $15.00. Surpassing the previous average price target of $16.86, the current average has increased by 3.8%.

bigjpg

Analyzing Analyst Ratings: A Detailed Breakdown

The...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment